MX9302057A - Metodo para el tratamiento de imdividuos seropositivos de vih con proteinas dieteticas de suero de leche. - Google Patents

Metodo para el tratamiento de imdividuos seropositivos de vih con proteinas dieteticas de suero de leche.

Info

Publication number
MX9302057A
MX9302057A MX9302057A MX9302057A MX9302057A MX 9302057 A MX9302057 A MX 9302057A MX 9302057 A MX9302057 A MX 9302057A MX 9302057 A MX9302057 A MX 9302057A MX 9302057 A MX9302057 A MX 9302057A
Authority
MX
Mexico
Prior art keywords
dietetic
proteins
treatment
seropositive individuals
milk serum
Prior art date
Application number
MX9302057A
Other languages
English (en)
Inventor
Phil Gold
Gustavo Bounous
Original Assignee
Immunotec Res Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunotec Res Corp Ltd filed Critical Immunotec Res Corp Ltd
Publication of MX9302057A publication Critical patent/MX9302057A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describe una composición farmacéutica que incluye un concentrado de proteína de suero de leche desnaturalizada, la cual se administra a individuos seropositivos de VIH, para elevar sus células monocleares de la sangre, su nivel de glutationa (GSH), su peso corporal, y sus sentido de bienestar. En adición, se eleva ligeramente la concentración de células de ayuda T y su relación de células de ayuda T/células supresoras T.
MX9302057A 1992-04-10 1993-04-07 Metodo para el tratamiento de imdividuos seropositivos de vih con proteinas dieteticas de suero de leche. MX9302057A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/866,756 US5456924A (en) 1988-12-23 1992-04-10 Method of treatment of HIV-seropositive individuals with dietary whey proteins

Publications (1)

Publication Number Publication Date
MX9302057A true MX9302057A (es) 1994-07-29

Family

ID=25348339

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9302057A MX9302057A (es) 1992-04-10 1993-04-07 Metodo para el tratamiento de imdividuos seropositivos de vih con proteinas dieteticas de suero de leche.

Country Status (19)

Country Link
US (1) US5456924A (es)
EP (1) EP0634934B1 (es)
JP (1) JP2738592B2 (es)
KR (1) KR100297959B1 (es)
CN (1) CN1070371C (es)
AT (1) ATE187335T1 (es)
AU (1) AU687731B2 (es)
CA (1) CA2090186C (es)
CZ (1) CZ283386B6 (es)
DE (1) DE69327236T2 (es)
DK (1) DK0634934T3 (es)
ES (1) ES2143503T3 (es)
IL (1) IL105339A (es)
MX (1) MX9302057A (es)
NO (1) NO317795B1 (es)
NZ (1) NZ251271A (es)
TW (1) TW384223B (es)
WO (1) WO1993020831A1 (es)
ZA (1) ZA932526B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5531989A (en) 1994-10-28 1996-07-02 Metagenics, Inc. Immunoglobulin and fiber-containing composition for human gastrointestinal health
US6241983B1 (en) 1994-10-28 2001-06-05 Metagenics, Inc. Bacteria-and fiber-containing composition for human gastrointestinal health
US5985275A (en) * 1995-04-12 1999-11-16 New York Blood Center β-Lactoglobulin modified with aromatic anhydride compound for preventing HIV infection
CA2165937A1 (en) * 1995-05-09 1996-11-10 Immunotec Research Corporation Ltd. Process for producing an undenatured whey protein concentrate
EP0915661A4 (en) * 1996-03-06 2004-09-08 Belloch Corp I PROCESS FOR TREATING LIQUID MATERIALS
AU1707197A (en) * 1996-03-20 1997-10-10 New York Blood Center, Inc., The Methods of treating herpes or chlamydia
US5952009A (en) * 1996-03-20 1999-09-14 New York Blood Center Methods for preventing the transmission of or treating patients infected with herpesvirus
WO1999055326A1 (en) 1998-04-30 1999-11-04 Vit-Immune, L.C. Method of treatment of glutathione deficient mammals
US6667063B2 (en) 1998-06-10 2003-12-23 Albert Crum Nutritional or therapeutic supplement and method
WO1999064022A1 (en) * 1998-06-10 1999-12-16 Crum Albert B Prophylactic and therapeutic nutritional supplement for creation/maintenance of health-protective intestinal microflora and enhancement of the immune system
US6203805B1 (en) 1998-11-10 2001-03-20 Color Access, Inc. Topical compositions containing whey proteins
US6864242B2 (en) 2001-03-05 2005-03-08 Stephen P. Ernest Enteral formulation
US6503506B1 (en) * 2001-08-10 2003-01-07 Millenium Biotechnologies, Inc. Nutrient therapy for immuno-compromised patients
EP1458247B1 (en) 2001-12-20 2014-01-22 Biolactis Inc. Malleable protein matrix and uses thereof
FR2840318B1 (fr) * 2002-05-29 2004-12-03 Quoc Kiet Pham Nouveaux sulfolipides antiretroviraux extraits de spirulines, leur procede d'obtention, les compositions les contenant et leur utilisation comme inhibiteurs de la transcriptase inverse des virus vih
FR2889067B1 (fr) * 2005-07-29 2011-11-11 Cie Laitiere Europeenne "utilisation d'une fraction proteique laitiere pour preparer une composition amincissante et/ou ameliorant la composition corporelle"
DE102006052504A1 (de) 2006-11-06 2008-05-08 Temper, Rupert Verfahren zum Herstellen eines Mittels gegen eine Infektionskrankheit
US20080119386A1 (en) * 2006-11-22 2008-05-22 Carl Germano Nutritional formula for athletes' recovery
WO2008095276A1 (en) * 2007-02-06 2008-08-14 Cymcorp International, Inc. Novel non-toxic composition and method of using such for treating a degenerative or an immune system-related disease
US20100069288A1 (en) * 2008-09-12 2010-03-18 Wulf Droge Use of cysteine-rich whey derived protein in patients receiving chemotherapy or radiotherapy to improve patient survival
JP2013079216A (ja) 2011-10-04 2013-05-02 Snow Brand Milk Products Co Ltd 感覚改善剤
JP6234777B2 (ja) * 2013-10-31 2017-11-22 株式会社日立製作所 光多値送信器および光トランスポンダ
DE102014001037A1 (de) * 2014-01-25 2015-07-30 Gea Tds Gmbh Verfahren und Vorrichtung zur Reduzierung des Wachstums thermophiler Keime in Magermilch
WO2018057514A1 (en) 2016-09-23 2018-03-29 Immunotec Inc. Compositions for restoring gene expression in neuropsychiatric or neurodegenerative disorders
CA2970699A1 (en) 2017-06-14 2018-12-14 Elizabeth E. Ignowski Compositions for increasing resilience to traumatic brain injury
WO2019027974A1 (en) 2017-07-31 2019-02-07 Immunotec Inc. COMPOSITIONS AND METHODS FOR TREATING AUTISM SPECTRUM DISORDER

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA858533A (en) * 1970-12-15 Lahav Eitan Polypeptidic antibiotic substances derived from casein by fermentation
FR2565985B1 (fr) * 1984-06-19 1987-09-25 Rhone Poulenc Sante Nouvelles substances biologiquement actives obtenues a partir de la caseine bovine, leur procede de preparation et les compositions qui les contiennent
US4880626A (en) * 1985-01-18 1989-11-14 Mcmichael John Immunotherapeutic methods and compositions for the treatment of diseases of viral origin, including acquired immune deficiency syndrome
US4983387A (en) * 1986-05-19 1991-01-08 Viral Technologies Inc. HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus
US5030449A (en) * 1988-07-21 1991-07-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Synthetic vaccine against AIDS virus
DE58904683D1 (de) * 1988-04-19 1993-07-22 Biotest Pharma Gmbh Praeparat mit antikoerperaktivitaet und breitem wirkungsspektrum, daraus bestehende oder diese enthaltende mittel und deren verwendung zur behandlung von bakteriell oder toxin-bedingten erkrankungen und zur bekaempfung von protozoen.
CA1333471C (en) * 1988-04-29 1994-12-13 Gustavo Bounous Whey protein concentrate as food supplement
CA1338682C (en) * 1988-12-23 1996-10-29 Gustavo Bounous Biologically active undenatured whey protein concentrate as food supplement
CA2007258A1 (en) * 1989-01-11 1990-07-11 Richard L. Jackson Heparin fraction with anti-hiv activity
DK0385909T3 (da) * 1989-03-03 1994-08-15 Microgenesys Inc Kit eller middel til forebyggelse eller behandling af HIV-1-infektioner
DE69028684T2 (de) * 1989-06-02 1997-05-22 The Johns Hopkins University School Of Medicine, Baltimore, Md. Gegen die beta-kette des leukozyten-adhäsions-rezeptors gerichtete monoklonale antikörper, verfahren zu ihrer herstellung und ihre verwendung
CA2022394A1 (en) * 1989-08-07 1991-02-08 Allen I. Oliff Peptide inhibitors of human papilloma virus protein binding to retinoblastoma gene proteins
DK0790255T3 (da) * 1989-12-22 2007-11-26 Hoffmann La Roche Monoklonale antistoffer som er rettet mod den cytotoksiske lymfocytmodningsfaktor
US5112373A (en) * 1991-06-17 1992-05-12 Hung Pham Apparatus for controlling and eliminating vapor emissions at a manicure work station

Also Published As

Publication number Publication date
CA2090186C (en) 1999-03-16
CZ246194A3 (en) 1995-04-12
NO317795B1 (no) 2004-12-13
CN1083704A (zh) 1994-03-16
NZ251271A (en) 1998-05-27
TW384223B (en) 2000-03-11
NO943804D0 (no) 1994-10-07
ATE187335T1 (de) 1999-12-15
EP0634934B1 (en) 1999-12-08
DK0634934T3 (da) 2000-06-13
IL105339A0 (en) 1993-08-18
AU3881293A (en) 1993-11-18
CN1070371C (zh) 2001-09-05
CA2090186A1 (en) 1993-10-11
JPH07504677A (ja) 1995-05-25
WO1993020831A1 (en) 1993-10-28
US5456924A (en) 1995-10-10
CZ283386B6 (cs) 1998-04-15
EP0634934A1 (en) 1995-01-25
KR100297959B1 (ko) 2001-10-24
KR950700752A (ko) 1995-02-20
DE69327236D1 (de) 2000-01-13
AU687731B2 (en) 1998-03-05
ES2143503T3 (es) 2000-05-16
IL105339A (en) 1998-07-15
NO943804L (no) 1994-10-07
DE69327236T2 (de) 2000-03-30
ZA932526B (en) 1994-03-09
JP2738592B2 (ja) 1998-04-08

Similar Documents

Publication Publication Date Title
MX9302057A (es) Metodo para el tratamiento de imdividuos seropositivos de vih con proteinas dieteticas de suero de leche.
Baruchel et al. Whey proteins as a food supplement in HIV-seropositive individuals
IE832394L (en) Immunogenic protein or peptide complex vaccine.
DE3689447D1 (de) Rekombinantes Viren-Überzugsprotein assoziiert mit "Acquired Immune Deficiency Syndrome" (AIDS) und Verfahren zur Testung von AIDS.
Miller et al. Plasmodium falciparum: thiol status and growth in normal and glucose-6-phosphate dehydrogenase deficient human erythrocytes
SE8505047D0 (sv) Fettemulsion
Houck et al. Induction of collagenolytic and proteolytic activities in rat and human fibroblasts by anti-inflammatory drugs
TR200101773T2 (tr) Yumurta sarìsìndan yiyecek olarak retilen anti-sekretuar proteinler.
Powell et al. Electrophorus acetylcholinesterase: A glycoprotein; molecular weight of its subunits
Grisolia et al. Inactivation of enzymes by aspirin and salicylate
Banerjee et al. Salivary peroxidases
DE68913386D1 (de) Selektive enzymatische Zersetzung von beta-Lactoglobulin in Molkeeiweiss von Kuhmilch.
Lewis et al. The Selective Membrane Filtration of an ESF-generating Factor (EGF) in the Presence of Erythropoietin (ESF)
Johnson et al. Artificial gut bioassay system- Influence of ascorbic acid on the bio-availability of iron from hydroponic spinach using human Caco-2 cell line(Abstract only)
DE59611330D1 (de) Arzneimittel enthaltend wenigstens einen teil des ul84-proteins des cytomegalovirus, verwendung von polypeptiden entsprechend der aminosäuresequenz des ul84-proteins und verfahren zur einführung von ul84 in zielzellen
Chandrasekhar Minor proteins in human erythrocytes
Keller Some factors affecting the cytotoxic immune reaction of rat mast cells
NZ243860A (en) Increasing glutathione levels in human and animal organs using whey protein concentrate
Esievo Variations in hematologic parameters among high-producing dairy cattle on high and low protein diets; Effects of protein intake and stage of lactation on hematological constituents and activities of red blood cell enzymes of high-producing dairy cattle; Hemoglobin-binding proteins (Haptoglobin-Hp) in normal healthy dairy cattle sera
築山恭子 et al. Bovine platelet-derived factor showing mitogenic activity on bovine leukemia virus-infected lymphocytes.
NAKAJIMA The Enzymatic Degradation of Heme Proteins into Bile Pigments. XI (1) The Enzymatic Degradation of Hemoglobin-haptoglobin Complex into a Precursor of Biliverdin. I
RU93007349A (ru) Способ производства сливочного ликера
Ilyinskikh THE FATE AND THE ORIGIN OF MICRONUCLEI ARE DIFFERENT